H.C. Wainwright raised the firm’s price target on Ocular Therapeutix (OCUL) to $21 from $19 and keeps a Buy rating on the shares.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Strategic Early Approval Pathway for Ocular Therapeutix’s Axpaxli Bolsters Buy Rating
- Ocular Therapeutix Prepares NDA Submission for Wet AMD Drug
- Ocular Therapeutix reports inducement grant under Nasdaq listing rule
- Promising Developments in Ocular Therapeutix’s Clinical Trials Support Buy Rating
- Ocular Therapeutix announces first patient randomized in HELIOS-3 program